<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9761">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690802</url>
  </required_header>
  <id_info>
    <org_study_id>TQXB-R-001</org_study_id>
    <nct_id>NCT05690802</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV</brief_title>
  <acronym>TSEPHCC</acronym>
  <official_title>Palonosetron Hydrochloride Capsules (Ruoshan ®) Used to Prevent and Control Chemotherapy for Tumor Patients Real World Study on the Safety of Nausea and Vomiting Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in&#xD;
      preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The&#xD;
      characteristics of the applicable population, clinical medication and clinical benefits of&#xD;
      Palonosetron Hydrochloride Capsules were analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, as the mainstream antiemetics of CINV, oral administration is the most commonly&#xD;
      used method of drug therapy. Clinical studies showed that there was no difference in the&#xD;
      efficacy of 5-HT3 receptor antagonist between different administration routes (oral and&#xD;
      intravenous). At the same time, because the oral route is the most convenient, oral&#xD;
      preparations provide more and more convenient choices for clinicians and patients. To observe&#xD;
      and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing&#xD;
      acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the&#xD;
      applicable population, clinical medication and clinical benefits of Palonosetron&#xD;
      Hydrochloride Capsules were analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2022</start_date>
  <completion_date type="Anticipated">May 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Palonosetron hydrochloride capsules</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any adverse event after treatment</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1060</enrollment>
  <condition>Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Palonosetron hydrochloride capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The recommended dose for adults is 0.5mg (1 capsule) for a single oral dose about 1 hour before chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron hydrochloride capsules</intervention_name>
    <description>This protocol only stipulates &quot;Palonosetron capsule containing hydrochloric acid protocol&quot;, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage.</description>
    <arm_group_label>Palonosetron hydrochloride capsules</arm_group_label>
    <other_name>Ruoshan ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For patients with malignant tumors who can accept chemotherapy, the disease type is&#xD;
             not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate&#xD;
             risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor&#xD;
             treatment related nausea and vomiting prevention and treatment guidelines);&#xD;
&#xD;
          -  18-75 years old, KPS score ≥ 70, and the expected survival time is more than 3 months;&#xD;
&#xD;
          -  Before treatment, ECG, blood routine test, liver and kidney functions and electrolytes&#xD;
             were basically normal;&#xD;
&#xD;
          -  All patients signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chemotherapy contraindications, patients allergic to 5-HT3RA, pregnant&#xD;
             women and lactating women;&#xD;
&#xD;
          -  People with digestive tract obstruction; Patients with serious heart disease, liver&#xD;
             and kidney disease and metabolic disorder; Patients suffering from epilepsy or using&#xD;
             psychotropic and sedative drugs;&#xD;
&#xD;
          -  Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before&#xD;
             treatment may have brain metastasis, intracranial hypertension, gastrointestinal&#xD;
             obstruction, psychological abnormalities, etc.Patients with factors causing nausea and&#xD;
             vomiting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu Hong, master</last_name>
    <role>Study Chair</role>
    <affiliation>Air Force Military Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Hong, master</last_name>
    <phone>13709284513</phone>
    <email>hongliu1@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Zhou, master</last_name>
    <phone>13720542643</phone>
    <email>252376698@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, the Air Force Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Hong, master</last_name>
      <phone>13709284513</phone>
      <email>hongliu1@fmmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 18, 2023</last_update_submitted>
  <last_update_submitted_qc>January 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

